Posted on October 7, 2019 by GlycoMark USA
New York, NY (October 7, 2019) — GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain. The GlycoMark test, an FDA-cleared and CE marked blood test used…
Read More
Posted on June 13, 2019 by GlycoMark USA
New York, NY (June 13, 2019)— GlycoMark, Inc. announced a new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with Type 2 diabetes that are being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to…
Read More
Posted on June 4, 2019 by GlycoMark USA
New York, NY (June 4, 2019) — GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco. The GlycoMark test, an FDA-cleared and CE-marked blood test used to monitor glycemic control in patients…
Read More
Posted on November 18, 2018 by GlycoMark USA
New York, NY (November 19, 2018)– LabFinder.com, a convenient online platform for patients to schedule their laboratory and radiology tests and access test results, has announced the addition of the GlycoMark® test to its growing subscriber network. The GlycoMark test is an FDA-cleared blood test for detecting recent hyperglycemia and hyperglycemic excursions in patients with…
Read More
Posted on November 7, 2018 by GlycoMark USA
New York, NY (November 7, 2018)— GlycoMark, Inc. and PrismHealthDx, Inc. (PHDx) have announced an agreement to offer the GlycoMark® test to clinicians managing patients with diabetes. The GlycoMark test is the only FDA-cleared blood test for patients with diabetes that is specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring while fasting, postprandial, or…
Read More
Posted on November 5, 2018 by Chermaen Lindberg
New York, NY (November 5, 2018)—GlycoMark, Inc., the exclusive provider of the GlycoMark® test, is launching live educational support for healthcare professionals through its website, https://glycomark.com/, as part of National Diabetes Month. The new complimentary educational support will offer a live chat and video option via the website in November from 9 a.m. – 5…
Read More
Posted on September 28, 2018 by Kirsten Dorsey
Join us while exhibits are open on October 6 to have your blood drawn by Accu Reference Medical Lab, a preferred GlycoMark lab partner and proud sponsor of conference attendee testing. The GlycoMark test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).…
Read More
Posted on September 25, 2018 by Kirsten Dorsey
New York, NY. Sept. 25th, 2018 – GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark test…
Read More
Posted on September 11, 2018 by Kirsten Dorsey
Visit GlycoMark’s booth the Cardiometabolic Risk Summit in San Antonio, TX on September 14-15, 2018, to learn more about the GlycoMark test. This test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both). To schedule a meeting with one of our experts,…
Read More
Posted on July 6, 2018 by GlycoMark USA
Visit booth #748 at AADE18 organized by the American Association of Diabetes Educators in Baltimore, MD on August 17-20, 2018, to learn more about the GlycoMark test. This test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both). To schedule a meeting…
Read More
The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.